Diabetes drugs

The research team at UU have discovered that modified-forms of GIP, a naturally occurring molecule produced by the body, can combat key symptoms of diabetes. This stimulated the formation of a new company to develop production of new anti-diabetic agents.
Current statistics report some 150 million diagnosed cases of diabetes worldwide, and that figure is set to double within 20 years, according Dr. Neville McClenaghan, a prime mover in the new company Diabetica Limited.
“The holy grail of diabetes treatment is safe and effective management of blood glucose. We believe that novel molecules arising from our platform GIP technology should provide effective new tools to help individuals better control the condition known as Type 2 diabetes,” he said.
“That’s really what physicians are looking for at the minute - new drugs that offer improvements or enhancement over current drugs.”
Register now to continue reading
Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.
Benefits of registering
-
In-depth insights and coverage of key emerging trends
-
Unrestricted access to special reports throughout the year
-
Daily technology news delivered straight to your inbox
Construction industry lags in tech adoption
Are these the best people to ask "Insights from 2,000 Industry Leaders"? - what would their customers views be like (perhaps more...